genOway

Since 1999, genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs.

We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions.

At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research.

What We Offer

• A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders

• Custom-made models tailored to specific research goals

• Proof-of-concept experiments aligned with model design and project needs

What Makes Us Unique

• Scientific Excellence: Our models have contributed to peer-reviewed publications and IND approvals.

• Easy access to the models: High-health-status models sourced from certified breeders in the US and Europe

• Strong Collaborations: Models co-validated with pharma and biotech partners

• Full Freedom to Operate: Secure use of technologies with guaranteed FTO in the specific field

Our Commitment to Sustainability

Through the genOway Low-Carbon Project, launched in 2021, we’ve committed to reducing our greenhouse gas emissions by 6% annually over a period of 5 years, by rethinking lab operations, logistics, and energy use. We’re proud to report that this initiative has already delivered measurable results, putting us on track to meet our reduction targets.